This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novo Nordisk Inc.
proportion of glycosylated haemoglobin
Reference
Langer J, et al. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. Journal of Managed Care Pharmacy 19: 237-46, No. 3, Apr 2013. Available from: URL: http://dx.doi.org/2013(19)3: 237-246 [pii]
Rights and permissions
About this article
Cite this article
Liraglutide beats sitaglitpin for T2DM in the USA. PharmacoEcon Outcomes News 676, 6 (2013). https://doi.org/10.1007/s40274-013-0319-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0319-4